Researchers at MD Anderson have launched a first-of-its-kind clinical trial for a particular type of treatment-resistant prostate cancer. They’re combining two drugs — abiraterone and enzalutamide — to block the resistance pathways that arise in each drug alone. The goal is to decrease the levels of testosterone that drive the cancer.
About Prostate Cancer
The best new therapies
Researchers at MD Anderson are working hard to develop a deeper understanding of the biology of prostate cancer and a new array of therapies that can control the disease and preserve patients’ quality of life.